Takeda Pharmaceutical Co. Ltd.'s Fiscal Year is From April To March - All Figures are in JPY, Billions.
The item "Net-Income-Applicable-To-Common-Shares" stands at 33.08 Billion Japanese Yens for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 03/31/2020.
Takeda Pharmaceutical Co. Ltd.'s second quarter result of -11.80 Billion JPY for the item "Net Income Applicable To Common Shares" represents a decrease of -109.50 percent compared to it's first quarter result.
Also, Takeda Pharmaceutical Co. Ltd.'s second quarter result of -11.80 Billion JPY for the item "Net Income Applicable To Common Shares" represents a decrease of -112.82 percent compared to it's second quarter result of last year.
Looking again at the trailing twelve months series (TTM), Takeda Pharmaceutical Co. Ltd.'s second quarter result of 33.08 Billion JPY for the item "Net Income Applicable To Common Shares" represents a decrease of -75.84 percent compared to it's first quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an decrease of -256.92 Billion Japanese Yens compared to the value the year prior.
The 1 year change is -256.92 Billion Japanese Yens.
The 3 year change is -180.05 Billion Japanese Yens.
The 5 year change is -64.53 Billion Japanese Yens.
The 10 year change is 185.90 Billion Japanese Yens.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Net Income Applicable To Common Shares | 905,699,262,464.00 |
![]() | Johnson & Johnson - Net Income Applicable To Common Shares | 486,508,953,600.00 |
![]() | AbbVie Inc - Net Income Applicable To Common Shares | 399,570,305,024.00 |
![]() | Roche Holding AG - Net Income Applicable To Common Shares | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Net Income Applicable To Common Shares | 280,205,508,085.11 |